Background: Nocturnal enuresis affects 5% to 10% of in the United States; an estimated to be 5 to 7 million kids. It affects all 7-year-olds, and it is more prevalent in boys. About 15% of cases are spontaneously cured each year, although 2% to 3% of children continue to experience symptoms as adults. Objective: The aim of the current study was to evaluate the safety and effectiveness of Mirabegron for treatment of NE. Patients and methods: A one-arm clinical trial was carried out at the Pediatric Unit, Urology Department, Zagazig University Hospital. A total 36 patients with monosymptomatic nocturnal enuresis (MNE) were enrolled in the study. All patients received mirabegron 25mg for 3 months at bedtime, together with some strategies for parents to help children who are wetting the bed. Results: The age of participants ranged from 7 to 15 with a mean of 9.8 (SD 2.5) years. Sex distribution was 20 (55.2%) males and 16 (44.4%) females. The duration of the study ranged from 6-12 months. There was a significant decrease in the mean bed wet after six months from treatment compared with the mean before treatment (P<0.05). After six months of treatment with Mirabegron, 10 (31.3%) parents reported complete response, 13 (40.6%) had partial response, and 9 (28.1%) had no response to treatment. Adverse effects were reported in 5 (13.9%) patients; constipation in 3 (8.3%) patients and dry mouth in 2 (5.5%) patients. Conclusion: Mirabegron, a brand-new, first-in-class medication, surfaced as a secure and reliable substitute for children with NE. More research including more patients and a longer period of follow-up is needed.